WEE1i-ATRi combination therapy: a promising low-dose treatment for CCNE1-amplified gynecologic cancers

CCNE1 amplification is an oncogenic driver for many gynecologic cancers and is associated with poor patient outcomes. In this issue, Xu et al.(1) identify a combination therapy that is responsive to high CCNE1-copy number ovarian and endometrial cancers using PDX models.